Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Monday, September 24, 2018

uBiome Expands Product Portfolio, Drug Discovery & Development

uBiome Announces $83 Million Series C Financing

uBiome Will Expand World’s Largest Human Microbiome Database 
and Advance Product Portfolio, 
Including Drug Discovery & Development
September 21, 2018

Considered to be "the leader in microbial genomics", uBiome announces that it has received $83 Million Series C Financing to expand its world's largest human microbiome database, advance product portfolio, drug discovery & development.

Proceeds of the financing will be used to:
  • Enhance and expand the Company’s product portfolio
  • Leverage insights gained by building largest microbiome database to expand into drug research and development using pre-existing patent assets and industry research collaborations, not data sales
  • Accelerate and expand commercialization of SmartGut, SmartJane, Explorer and other clinical tests under development, including companion diagnostics
  • Begin commercialization of biopharma molecules and live biotherapeutics based on mining of existing IP

uBiome has partnered with more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, University of California, San Francisco, the Massachusetts Institute of Technology, Oxford University, and the University of Sydney.

MEBO is currently participating in the uBiome's database expansion. It is our hope, though not a guarantee...that this clinical trial will ultimately lead to drug discovery & development.
With a uBiome Research Grant sponsoring MEBO's Clinical Trial, NCT02683876, "Microbial Basis of Systemic Malodor and PATM Conditions", MEBO is currently participating in the uBiome's database expansion. It is our hope, though not a guarantee, as stated in MEBO's Research Consent Form, that this clinical trial will ultimately lead to drug discovery & development.

The international MEBO community is most grateful to uBiome for the research grant it has awarded us for our Clinical Trial. We look forward to uBiome's expansion of its advanced product portfolio and drug discovery and development, which we hope will help our community arrive at proper diagnoses and targeted, personalized treatment protocols moving forward.


María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization


Anonymous said...

I have read that fecal transplant could help, but in the US it can't be done unless you have c-diff. Why, is there is a chance to help people is it limited to patients with c-diff. People are committing suicide over this malodor disorder and the FDA does not care I guess

Oct 13, 2018, 11:22:00 PM
Post a Comment